He received his Ph.D. from Institute of Medical Science, The University of Tokyo in 1994. He was research training as a graduate student in Virology Division (late professor Hiroshi Shibuta), at Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo Japan until 1991. He investigated and elucidated the molecular mechanism of human immunodeficiency virus (HIV) type 1 particle formation for development of New AIDS vaccination system using recombinant vaccinia virus. He was research training as a resident staff in Virology Division (Division Chief, Dr. Kunitada Shimotohno), at National Cancer Center, Tokyo Japan for 3 years until 1994 and joined Whitehead Institute for Biomedical research (W.I.B.R.) at Massachusetts Institute of Technology (M.I.T.) that year. He did postdoctoral training in the laboratory of Dr. Richard A. Young (W.I.B.R. at M.I.T., Membership of National Academy of Sciences), and also was a research member of Project of New England AIDS vaccine development (Project Leader: Dr. David Baltimore, Nobel Laureate 1975, Honorary president, California Institute of Technology). After postdoctoral training, he got faculty position Lectuer, Massachusetts General Hospital (M.G.H.) at Harvard Medical School (H.M.S.) in 1997. He has been studying the sarcomagenesis of human uterine leiomyosarcomas with proteasome b subunit LMP2-deficient mice, under the research co-operation of Dr. Susumu Tonegawa (Nobel Laureate 1987, the Picower Institute for Learning and Memory at M.I.T.). He identifies diagnostic biomarkers, LMP2, Cyclin B1 and Cyclin E, which distinguish human malignant tumour uterine leiomyosarcoma from other human uterine mesenchymal tumours including benign tumour uterine leiomyoma. He also focus physiological significance of NF-kBp50 in survival of central nerves cells.

Current research focus: molecular approach of tumourigenesis of human uterine mesenchymal tumours, especially uterine leiomyosarcoma, and other research filed; neuronal cell survival of central nerves system.